Related Experiment Video
Updated: Jan 6, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
18.2K
Biosimilar Uptake in Spain from 2016 to 2023: Analysis Based on Official Data Collection
Jaime Espin1,2,3, Zuzana Špacírová4,5, Leticia García-Mochón1,2,3
1Andalusian School of Public Health/Escuela Andaluza de Salud Pública (EASP), Granada, Spain.
Summary
Biosimilar medicine use in Spain rose significantly from 9% in 2016 to 47% in 2023. Hospital settings and acute condition biosimilars showed higher uptake, with more competitors boosting market share in hospitals.
Area of Science:
- Pharmacoeconomics and Health Policy
- Drug Utilization Research
- Biopharmaceutical Market Analysis
Background:
- Limited public data on biosimilar uptake exists in most European countries, hindering comprehensive analysis.
- Spain lacks regularly published nationwide data on biosimilar consumption and market penetration.
Purpose of the Study:
- To conduct a nationwide assessment of biosimilar consumption and uptake patterns in Spain from 2016 to 2023.
- To analyze factors influencing biosimilar market share, including setting, indication type, and competitor numbers.
Main Methods:
- Utilized nationwide data on biosimilar defined daily doses (DDD) dispensed via community pharmacies and hospitals.
- Employed non-parametric tests and bootstrap analysis (10,000 replications) to analyze market share, time since entry, competitor count, and indication type.
- Included data on bio-originator and biosimilar registration status for each active principle.
Main Results:
- Biosimilar penetration in Spain increased from 9% in 2016 to 47% in 2023.
- In 2023, hospital settings showed higher biosimilar market share (68%) than community pharmacies (34%).
- Biosimilars for acute conditions had higher market shares than those for chronic conditions; a positive correlation between market share and competitor numbers was significant in hospitals.
Conclusions:
- Biosimilar utilization in Spain has grown substantially, with significant differences between hospital and community pharmacy settings.
- The type of condition treated (acute vs. chronic) and the number of competitors influence biosimilar market share, particularly in hospitals.
- Further research into policies promoting biosimilar adoption is recommended to optimize their use in Spain.
More Related Videos
08:01Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
Published on: November 30, 2022
5.4K
06:173D Human Myocardial Tissue Generation Using Melt Electrospinning Writing of Polycaprolactone Scaffolds and hiPSC-Derived Cardiac Cells
Published on: March 28, 2025
970
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
208
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
208
01:16Bioequivalence: Overview
1.6K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.6K
01:13Bioequivalence studies: Biowaivers
197
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
197
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
134
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
134
01:13Bioavailability: Overview
3.9K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
3.9K
01:17Bioavailability: Overview
310
Bioavailability refers to the proportion of an administered drug that reaches the systemic circulation in its active, unaltered form. It is a crucial pharmacokinetic parameter that determines the effectiveness of a drug in achieving its intended therapeutic outcomes. The route of administration significantly influences bioavailability, with intravenous administration achieving 100% bioavailability as the drug directly enters the bloodstream. In contrast, oral administration often results in...
310